[New aspects in the treatment of thyroid cancer : Highlights of the ASCO Annual Meeting 2016].
The annual meeting of the American Society of Clinical Oncology (ASCO) took place at the beginning of June 2016 in Chicago. This year a total of 28 studies on the treatment of patients with thyroid cancer were presented, described in this review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. In contrast, kinase inhibitors are being used increasingly within palliative concepts. The latest state of the art of thyroid cancer treatment, both surgical and medical, is summarized in this review.
Univ.-Klinik für HNO-Heilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. b.loerincz@uke.de.
B B
BB
Lörincz
Service d'ORL et chirurgie cervico-faciale, CHUV, Lausanne, Schweiz.
C
C
Simon
Univ.-Klinik für HNO-Heilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
N
N
Möckelmann
Univ.-Klinik für HNO-Heilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
R
R
Knecht
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000639:trends*; D003131:Combined Modality Therapy / Q000639:trends; D019317:Evidence-Based Medicine; D005260:Female; D005858:Germany; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D008297:Male; D058990:Molecular Targeted Therapy / Q000639:trends*; D010166:Palliative Care / Q000639:trends; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000628:therapy*; D013965:Thyroidectomy / Q000639:trends*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal
Kinase inhibitors; Metastasis; Palliative care; Surgery; Thyroid